JP2010539508A5 - - Google Patents

Download PDF

Info

Publication number
JP2010539508A5
JP2010539508A5 JP2010525420A JP2010525420A JP2010539508A5 JP 2010539508 A5 JP2010539508 A5 JP 2010539508A5 JP 2010525420 A JP2010525420 A JP 2010525420A JP 2010525420 A JP2010525420 A JP 2010525420A JP 2010539508 A5 JP2010539508 A5 JP 2010539508A5
Authority
JP
Japan
Prior art keywords
ccr4
pamphlet
tumor
activity
patient
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010525420A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010539508A (ja
JP5774309B2 (ja
Filing date
Publication date
Priority claimed from GB0718167A external-priority patent/GB0718167D0/en
Application filed filed Critical
Publication of JP2010539508A publication Critical patent/JP2010539508A/ja
Publication of JP2010539508A5 publication Critical patent/JP2010539508A5/ja
Application granted granted Critical
Publication of JP5774309B2 publication Critical patent/JP5774309B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010525420A 2007-09-18 2008-09-18 癌マーカーおよび治療ターゲット Expired - Fee Related JP5774309B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0718167A GB0718167D0 (en) 2007-09-18 2007-09-18 Cancer marker and therapeutic target
GB0718167.0 2007-09-18
PCT/GB2008/003160 WO2009037454A2 (en) 2007-09-18 2008-09-18 Cancer marker and therapeutic target

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015131752A Division JP6234967B2 (ja) 2007-09-18 2015-06-30 癌マーカーおよび治療ターゲット

Publications (3)

Publication Number Publication Date
JP2010539508A JP2010539508A (ja) 2010-12-16
JP2010539508A5 true JP2010539508A5 (enExample) 2012-10-04
JP5774309B2 JP5774309B2 (ja) 2015-09-09

Family

ID=38670078

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010525420A Expired - Fee Related JP5774309B2 (ja) 2007-09-18 2008-09-18 癌マーカーおよび治療ターゲット
JP2015131752A Expired - Fee Related JP6234967B2 (ja) 2007-09-18 2015-06-30 癌マーカーおよび治療ターゲット

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015131752A Expired - Fee Related JP6234967B2 (ja) 2007-09-18 2015-06-30 癌マーカーおよび治療ターゲット

Country Status (11)

Country Link
US (2) US9134293B2 (enExample)
EP (3) EP2533047B1 (enExample)
JP (2) JP5774309B2 (enExample)
AU (1) AU2008300413B2 (enExample)
CA (1) CA2699702C (enExample)
DK (3) DK2533047T3 (enExample)
ES (3) ES2443541T3 (enExample)
GB (1) GB0718167D0 (enExample)
PL (3) PL2533047T3 (enExample)
RU (2) RU2529797C2 (enExample)
WO (1) WO2009037454A2 (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0623815Y2 (ja) 1988-10-06 1994-06-22 株式会社大金製作所 エア回転継手のシール装置
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
US11029313B2 (en) 2008-09-26 2021-06-08 The General Hospital Corporation Method of treating cervical neoplasia in patients infected with human papilloma virus
WO2010037042A2 (en) 2008-09-26 2010-04-01 The General Hospital Corporation Methods for detecting and treating cancer
GB0909906D0 (en) * 2009-06-09 2009-07-22 Affitech As Antibodies
US20130095473A1 (en) * 2010-06-14 2013-04-18 Qiagen Gmbh Method for determination of target cells or tissue for extraction of biomolecules from fixed biological samples
GB201021289D0 (en) * 2010-12-15 2011-01-26 Immatics Biotechnologies Gmbh Novel biomarkers for a prediction of the outcome of an immunotherapy against cancer
GB201020738D0 (en) 2010-12-07 2011-01-19 Affitech Res As Antibodies
US10266599B2 (en) 2010-12-07 2019-04-23 Cancer Research Technology Limited Antibodies which bind to the human CC chemokine receptor 4 and uses thereof
US10195174B2 (en) 2011-10-24 2019-02-05 Signalchem Lifesciences Corporation Carbonic anhydrase IX-related markers and use thereof
EP2785692B1 (en) 2011-12-01 2017-09-27 ChemoCentryx, Inc. Substituted anilines as ccr(4) antagonists
GB2512857A (en) * 2013-04-09 2014-10-15 Cancer Res Technology Cancer biomarker
MY192757A (en) * 2013-11-06 2022-09-07 Janssen Biotech Inc Anti-ccl17 antibodies
AU2015266958A1 (en) 2014-05-28 2016-12-08 Agenus Inc. Anti-GITR antibodies and methods of use thereof
CA2962812A1 (en) * 2014-10-01 2016-04-07 Sphingotec Gmbh Hgh determination for use to guide prevention of a major adverse cardiac event or a cardiovascular disease in a subject
RU2718780C9 (ru) * 2015-04-17 2020-07-08 Эйсай Инк. Способы лечения рака легкого
EP3329244B1 (en) 2015-07-30 2022-10-05 Qiagen GmbH Method of preparing a frozen biological sample
SG10201912984WA (en) 2015-12-02 2020-03-30 Agenus Inc Antibodies and methods of use thereof
JP7177445B2 (ja) 2017-05-19 2022-11-24 真吾 前田 Ccr4阻害による制御性t細胞浸潤抑制法およびイヌの腫瘍性疾患の治療法
KR102817790B1 (ko) 2018-08-29 2025-06-05 케모센트릭스, 인크. C-c 케모카인 수용체 4(ccr4) 길항제 및 하나 이상의 면역 체크포인트 억제제를 사용한 병용 요법
EP3885452A1 (en) * 2020-03-23 2021-09-29 Koninklijke Philips N.V. Prediction of radiotherapy response for prostate cancer subject based on chemokine genes

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5786158A (en) * 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
US5342947A (en) * 1992-10-09 1994-08-30 Glaxo Inc. Preparation of water soluble camptothecin derivatives
EP0689606A1 (en) * 1993-03-19 1996-01-03 The Johns Hopkins University ANTIBODIES AND ASSAYS FOR DETERMINING MUTATIONS IN THE $i(APC) GENE
GB9501683D0 (en) 1995-01-27 1995-03-15 Glaxo Group Ltd Substances and their uses
US6498015B1 (en) 1995-06-07 2002-12-24 Icos Corporation Methods of identifying agents that modulate the binding between MDC and an MDC receptor
US6488930B1 (en) * 1999-01-15 2002-12-03 Millennium Pharmaceuticals, Inc. Anti-CCR4 antibodies and methods of use therefor
US6245332B1 (en) 1999-01-15 2001-06-12 The Board Of Trustees Of The Leland Stanford Junior University Modulation of systemic memory T cell trafficking
CA2401491C (en) 2000-03-03 2011-07-05 Kyowa Kirin Co., Ltd. Ccr4-binding antibody and diagnostic and therapeutic uses thereof
AU2002213466A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Compounds and methods for modulating ccr4 function
AU2002213467A1 (en) 2000-10-11 2002-04-22 Chemocentryx, Inc. Modulation of ccr4 function
BR0114696A (pt) 2000-10-18 2003-11-18 Schering Aktiengellschaft Uso de antiprogestinas para a indução de apoptose em uma célula
WO2002067771A2 (en) * 2001-02-28 2002-09-06 Protein Design Labs, Inc. Chemokine receptors and disease
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
NZ531069A (en) 2001-08-10 2007-01-26 Topigen Pharma Inc Methods for modulating viral infection of cells by modulating a binding interaction between a CCR1, CCR2, CCR3, CCR4, CCR5 and/or CCR8 receptor and a surface protein of the virus
CA2458627C (en) 2001-08-31 2013-09-10 Kyowa Kirin Co., Ltd. Human cdr-grafted antibody and antibody fragment thereof
EP1541563A4 (en) 2002-07-10 2007-11-07 Ono Pharmaceutical Co ANTAGONIST OF CCR4 AND CORRESPONDING MEDICINAL USE
US7919083B2 (en) 2002-11-15 2011-04-05 Morehouse School Of Medicine Anti-chemokine and associated receptors antibodies for inhibition of growth of neoplasms
EP2058408A3 (en) * 2003-02-14 2009-09-09 Sagres Discovery, Inc. Therapeutic GPCR targets in cancer
US7807389B2 (en) 2003-03-14 2010-10-05 University Of Rochester Methods and compositions related to joint inflammation diseases
SE0301650D0 (sv) 2003-06-04 2003-06-04 Astrazeneca Ab Novel compounds
SE0301653D0 (sv) 2003-06-05 2003-06-05 Astrazeneca Ab Novel compounds
EP1661889A4 (en) * 2003-09-05 2009-08-05 Ono Pharmaceutical Co ANTAGONIST OF THE CHEMOKINE RECEPTOR AND ITS USE FOR MEDICAL PURPOSES
CA2542037A1 (en) 2003-10-08 2005-04-21 Kyowa Hakko Kogyo Co., Ltd. Composition of antibody capable of specifically binding ccr4
EP1702625B1 (en) 2003-12-04 2010-11-03 Kyowa Hakko Kirin Co., Ltd. Medicine containing genetically modified antibody against chemokine receptor ccr4
WO2005082865A1 (ja) 2004-02-27 2005-09-09 Astellas Pharma Inc. 縮合二環性ピリミジン誘導体
JP2007217282A (ja) 2004-03-04 2007-08-30 Astellas Pharma Inc 置換ピリミジン誘導体
WO2005106471A2 (en) * 2004-04-30 2005-11-10 Bayer Healthcare Ag Diagnostics and therapeutics for diseases associated with c-c chemokine receptor 4 (ccr4)
JP2007269629A (ja) 2004-06-21 2007-10-18 Astellas Pharma Inc キナゾリン誘導体
RU2296328C1 (ru) * 2005-09-21 2007-03-27 Общество с ограниченной ответственностью "ГЕН" Способ определения предрасположенности к онкологическим заболеваниям и диагностический набор для его осуществления
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
ES2397803T3 (es) 2006-02-14 2013-03-11 Noxxon Pharma Ag Ácidos nucleicos de unión a MCP-1
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target

Similar Documents

Publication Publication Date Title
JP2010539508A5 (enExample)
RU2010123921A (ru) Раковый маркер и терапевтическая мишень
Zubair et al. Advanced approaches to breast cancer classification and diagnosis
Huang et al. Shear stress activates ATOH8 via autocrine VEGF promoting glycolysis dependent-survival of colorectal cancer cells in the circulation
JP4943504B2 (ja) 循環腫瘍細胞アッセイ
Tanaka et al. Inhibition of infiltration and angiogenesis by thrombospondin-1 in papillary thyroid carcinoma
JP2017184729A5 (enExample)
Han et al. Expression of PTEN and mTOR in pancreatic neuroendocrine tumors
JP6983221B2 (ja) 大腸癌の併用検査
JP2009511524A (ja) ケモカイン発現のegfr依存調節ならびに腫瘍とその副作用の治療及び診断に与えるケモカイン発現調節の影響
Hou et al. Detecting ALK-rearrangement of CTC enriched by nanovelcro chip in advanced NSCLC patients
JP2008514209A5 (enExample)
Ikuta et al. The current management of clear cell sarcoma
Liu et al. Neuroendocrine differentiation is predictive of poor survival in patients with stage II colorectal cancer
Wang et al. Relationship between RGS5 expression and differentiation and angiogenesis of gastric carcinoma
Sandri et al. Serum levels of HER2 ECD can determine the response rate to low dose oral cyclophosphamide and methotrexate in patients with advanced stage breast carcinoma
Obata et al. Association between single nucleotide polymorphisms of drug resistance-associated genes and response to chemotherapy in advanced ovarian cancer
CN116559462A (zh) 用于肿瘤患者预后的生物标志物组及其用途
JP2012085554A (ja) 乳がんのサブタイプの判別方法
JP2007523640A5 (enExample)
JP2012085555A (ja) 乳がん診断用マーカー
He et al. Three-dimensional nanostructured substrates enable dynamic detection of ALK-rearrangement in circulating tumor cells from treatment-naive patients with stage III/IV lung adenocarcinoma
JP6466911B2 (ja) Ccl22及びccl17癌生物マーカー
JP2008535491A5 (enExample)
JPWO2007099852A1 (ja) 固形癌のチロシンキナーゼ阻害剤に対する感受性を検査する方法及び検査キット